TITLE

GILEAD, MERCK, BRISTOL-MYERS TO COMBINE HIV DRUGS

PUB. DATE
July 2004
SOURCE
Clinical Infectious Diseases;7/1/2004, Vol. 39 Issue 1, piv
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Pharmaceutical companies Bristol-Myers Squibb Co., Gilead Sciences Inc., and Merck & Co. Inc., on Sunday said they are in talks to develop a combination of three anti-HIV drugs, after U.S. officials urged drug companies to provide better treatment options in developing countries. The companies said the once-daily, fixed-dose combination would include Viread and Emtriva, both Gilead drugs. It would also include efavirenz, marketed in the United States, Canada and certain European countries by Bristol-Myers as Sustiva. The move follows statements by Secretary of Health and Human Services Tommy Thompson calling on drug companies to develop new combination products, which would make often complicated drug regimens easier.
ACCESSION #
13602894

 

Related Articles

  • Key Infectious Announcements, May 15, 2004 -- June 14, 2004.  // PharmaWatch: Monthly Review;July 2004, Vol. 3 Issue 7, p23 

    Reports developments in pharmaceutical industry in the U.S. as of June 14, 2004. Plans of Bristol-Myers Squibb Co., Gilead Sciences Inc. and Merck & Co. Inc. to co-develop combination HIV medicine; Reaction of the World Health Organization to the U.S. Government's announcement of its expedited...

  • Infectious Diseases News Round-up.  // PharmaWatch: Monthly Review;July 2004, Vol. 3 Issue 7, p23 

    Reports developments in pharmaceutical industry in the U.S. as of July 2004. Plans of Bristol-Myers Squibb Co., Gilead Sciences Inc. and Merck & Co. Inc. to co-develop combination HIV medicine; Reaction of the World Health Organization to the U.S. Government's announcement of its expedited...

  • New generic launches buoy growth.  // Drug Store News;9/25/2006, Vol. 28 Issue 12, p26 

    The article reports on the expiration of patent licenses of major brand-name drugs which experts say the beginning of patent expirations of branded drugs spanning for 5 years in the U.S. Three of the major brand name drugs who lost its patent protection included Zocor manufactured by Merck...

  • Pipeline preview.  // Formulary;Oct2005, Vol. 40 Issue 10, p321 

    Reports on drugs in the pipeline for approval by the U.S. Food and Drug Administration. Nelarabine from GlaxoSmithKline for the treatment of T-cell acute lymphoblastic leukemia ad T-cell lymphoblastic lymphoma; Murglitazar from Merck/Bristol-Myers Squibb as monotherapy for type 2 diabetes;...

  • Pharmaceuticals in Canada.  // Pharmaceuticals Industry Profile: Canada;November 2004, p1 

    Presents a profile of the Pharmaceuticals industry in Canada. Background on Datamonitor, a business information company specializing in industry analysis; Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the...

  • Pharmaceuticals in France.  // Pharmaceuticals Industry Profile: France;January 2003, pN.PAG 

    Presents a profile of the Pharmaceuticals industry in France. Background on Datamonitor, a business information company specializing in industry analysis; Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the...

  • Pipeline.  // Medical Marketing & Media;Oct2014, Vol. 49 Issue 10, p14 

    This section offers news briefs relevant to the pharmaceutical industry as of October 2014 which include Merck and Co. Inc.'s phase 3 trial of its osteoporosis drug odanacatib and the approval of Bristol-Myers Squibb and Pfizer Inc.'s Eliquis for the treatment of pulmonary embolism.

  • Pharma rises on pipeline strength. Mirasol, Feliza // ICIS Chemical Business Americas;1/8/2007, Vol. 271 Issue 1, p32 

    The article reports that drug manufacturers are looking forward to new product launches and key regulatory filings in 2007 as a way to ensure sustainable growth. Merck has three compounds under review with the U.S. Food and Drug Administration including Arcoxia, Janumet and MK-0517 for nausea....

  • Reefer sanity. Wadman, Meredith // Fortune;11/24/2003, Vol. 148 Issue 11, p58 

    Reports that pharmaceutical companies are developing drugs that will hinder brain signals that trigger hunger. Focus on the cannabinoid receptor; Companies doing research into this area including Merck & Co. Inc., Pfizer Inc., and Bristol-Myers Squibb Co.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics